JP2011520983A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520983A5
JP2011520983A5 JP2011510720A JP2011510720A JP2011520983A5 JP 2011520983 A5 JP2011520983 A5 JP 2011520983A5 JP 2011510720 A JP2011510720 A JP 2011510720A JP 2011510720 A JP2011510720 A JP 2011510720A JP 2011520983 A5 JP2011520983 A5 JP 2011520983A5
Authority
JP
Japan
Prior art keywords
compound
oligonucleotide
independently
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011510720A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520983A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044953 external-priority patent/WO2009143412A2/en
Publication of JP2011520983A publication Critical patent/JP2011520983A/ja
Publication of JP2011520983A5 publication Critical patent/JP2011520983A5/ja
Pending legal-status Critical Current

Links

JP2011510720A 2008-05-23 2009-05-22 オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム Pending JP2011520983A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US5586908P 2008-05-23 2008-05-23
US5595008P 2008-05-23 2008-05-23
US61/055,950 2008-05-23
US61/055,869 2008-05-23
US10657808P 2008-10-19 2008-10-19
US10657608P 2008-10-19 2008-10-19
US61/106,576 2008-10-19
US61/106,578 2008-10-19
PCT/US2009/044953 WO2009143412A2 (en) 2008-05-23 2009-05-22 Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides

Publications (2)

Publication Number Publication Date
JP2011520983A JP2011520983A (ja) 2011-07-21
JP2011520983A5 true JP2011520983A5 (enExample) 2012-06-28

Family

ID=41340917

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510720A Pending JP2011520983A (ja) 2008-05-23 2009-05-22 オリゴヌクレオチドの送達のための細胞内遊離可能ジスルフィドリンカーを含有するポリマーシステム

Country Status (6)

Country Link
US (1) US20110105413A1 (enExample)
EP (1) EP2288261A4 (enExample)
JP (1) JP2011520983A (enExample)
CA (1) CA2723263A1 (enExample)
TW (1) TW201004648A (enExample)
WO (1) WO2009143412A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010536986A (ja) * 2007-08-20 2010-12-02 エンゾン ファーマシューティカルズ，インコーポレーテッド ピリジルジスルフィド部分を含有するポリマーリンカー
ITMI20131929A1 (it) * 2013-11-20 2015-05-21 Domenico Terenzio Coniugato dell'acido folico e dell'indolo-3-carbinolo per uso medico
CA2943609A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
SMT202200466T1 (it) 2016-01-08 2023-01-13 Ascendis Pharma Growth Disorders As Profarmaci di cnp con legame a supporto in corrispondenza del raggruppamento ciclico
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
EP3400022A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
WO2017118704A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
SMT202400423T1 (it) 2016-03-01 2024-11-15 Ascendis Pharma Bone Diseases As Profarmaci di pth
CA3030376A1 (en) 2016-07-13 2018-01-18 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
NZ792622A (en) 2016-09-29 2025-08-29 Ascendis Pharma Bone Diseases As Pth compounds with low peak-to-trough ratios
RS64440B1 (sr) 2016-09-29 2023-09-29 Ascendis Pharma Bone Diseases As Režim doziranja za pth jedinjenje sa kontrolisanim oslobađanjem
PT3518982T (pt) 2016-09-29 2025-01-29 Ascendis Pharma Bone Diseases As Descoberta da dose incremental em compostos de pth de libertação controlada
IL321464A (en) 2016-09-29 2025-08-01 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
MA52662A (fr) 2018-03-28 2021-02-17 Ascendis Pharma Oncology Div A/S Conjugués d'il-2
CA3093083A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
DK3793587T3 (da) 2018-05-18 2025-07-21 Ascendis Pharma Bone Diseases As Startdosis af pth-konjugater
WO2020064847A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
EP3856255A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Treatment of infections
EP3856256A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Novel hydrogel conjugates
CA3125541A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
WO2020141223A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Induction of sustained local inflammation
US20220054476A1 (en) 2019-01-04 2022-02-24 Ascendis Pharma Oncology Division A/S Sustained local drug levels for innate immune agonists
BR112021011592A2 (pt) 2019-01-04 2021-10-26 Ascendis Pharma Oncology Division A/S Conjugados de agonistas de receptor de reconhecimento de padrão
EP3923905A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Bone Diseases A/S Liquid pharmaceutical formulations of pth conjugates
US12377133B2 (en) 2019-02-11 2025-08-05 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of CNP conjugates
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
AU2020295725A1 (en) 2019-06-21 2021-12-02 Ascendis Pharma Oncology Division A/S Anti-CTLA4 conjugates
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
EP3986478A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
IL294357A (en) 2020-01-13 2022-08-01 Ascendis Pharma Bone Diseases As Hypoparathyroidism treatment
WO2021224169A1 (en) 2020-05-04 2021-11-11 Ascendis Pharma A/S Hydrogel irradiation
JP2023527919A (ja) 2020-06-03 2023-06-30 アセンディス ファーマ オンコロジー ディヴィジョン エー／エス Ｉｌ－２配列及びその使用
TW202219060A (zh) 2020-08-28 2022-05-16 丹麥商阿森迪斯腫瘤製藥有限公司 醣基化il-2蛋白及其用途
IL301411A (en) 2020-09-28 2023-05-01 Ascendis Pharma Bone Diseases As Improvement of physical and mental well-being of patients with hypoparathyroidism
MX2023011059A (es) 2021-04-01 2023-09-29 Ascendis Pharma As Uso de hormona del crecimiento de accion prolongada para tratamiento de enfermedades inducidas por inflamacion.
WO2022230990A1 (ja) * 2021-04-28 2022-11-03 国立研究開発法人科学技術振興機構 人工核酸及びそれを用いた核酸の送達方法
WO2023046732A1 (en) 2021-09-22 2023-03-30 Ascendis Pharma Bone Diseases A/S Long-acting pth compound treatments
AU2022409306A1 (en) 2021-12-13 2024-06-06 Ascendis Pharma Oncology Division A/S Cancer treatments with tlr7/8 agonists
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
JP2025522281A (ja) 2022-05-23 2025-07-15 アセンディス ファーマ グロース ディスオーダーズ エー／エス Ｃｎｐ化合物の液体医薬製剤
AU2023374533A1 (en) 2022-11-02 2025-04-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
TW202430223A (zh) 2023-01-05 2024-08-01 丹麥商阿仙帝斯眼科製藥有限公司 用於治療眼部病症之藥物結合物
TW202434299A (zh) 2023-01-05 2024-09-01 丹麥商阿仙帝斯製藥公司 製造水凝膠微球之方法
WO2024184354A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Multi-albumin binding compounds
TW202440150A (zh) 2023-03-06 2024-10-16 丹麥商阿仙帝斯製藥公司 具白蛋白結合部分之藥物化合物
WO2024184352A1 (en) 2023-03-06 2024-09-12 Ascendis Pharma A/S Drug compounds comprising albumin-binding moieties
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
AU2024270185A1 (en) 2023-05-09 2025-11-06 Ascendis Pharma Oncology Division A/S Novel cancer treatments with il-2 conjugates
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE268609T1 (de) * 1998-03-12 2004-06-15 Nektar Therapeutics Al Corp Polyethylenglycolderivate mit benachbarten reaktiven gruppen
ATE452654T1 (de) * 2001-11-09 2010-01-15 Enzon Inc Polyalkylenoxid-konjugate von thiolhaltigen arzneistoffen
MXPA05007348A (es) * 2003-01-06 2005-10-05 Nektar Therapeutics Al Corp Derivados de polimeros solubles en agua tiol-selectivos.
US20050266409A1 (en) * 2003-02-04 2005-12-01 Wyeth Compositions and methods for diagnosing, preventing, and treating cancers
KR20060015505A (ko) * 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
US7851565B2 (en) * 2004-12-21 2010-12-14 Nektar Therapeutics Stabilized polymeric thiol reagents
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
BRPI0716823A2 (pt) * 2006-09-15 2015-05-26 Enzon Pharmaceuticals Inc Conjunto poliméricos contendo porções positivamente carregadas
US8367065B2 (en) * 2006-09-15 2013-02-05 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
WO2008034124A2 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Targeted polymeric prodrugs containing multifunctional linkers
AU2008213576B2 (en) * 2007-02-09 2013-01-17 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
JP2010536986A (ja) * 2007-08-20 2010-12-02 エンゾン ファーマシューティカルズ，インコーポレーテッド ピリジルジスルフィド部分を含有するポリマーリンカー

Similar Documents

Publication Publication Date Title
JP2011520983A5 (enExample)
KR101328568B1 (ko) Ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도
JP2011529912A5 (enExample)
EP2796150B1 (en) Novel oligonucleotide conjugates and use thereof
CN104718295B (zh) 用于治疗奥尔波特综合征的方法
KR101752812B1 (ko) 고효율 나노입자형 이중나선 올리고 rna 구조체 및 그의 제조방법
JP2012509258A5 (enExample)
JP7154403B2 (ja) アンフィレグリン遺伝子特異的二重鎖オリゴヌクレオチド及びこれを含む線維症関連疾患及び呼吸器関連疾患の予防及び治療用組成物
ES2809481T3 (es) Estructura de oligonucleótidos de tipo nanopartícula mejorada que tiene alta eficiencia y método para preparar la misma
JP2015523853A5 (enExample)
JP2015502365A5 (enExample)
JP2015519057A5 (enExample)
Yan et al. microRNAs in cardiovascular disease: small molecules but big roles
CN114901821A (zh) Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
KR102701681B1 (ko) 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물
JP7579147B2 (ja) 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート
CN112055597A (zh) 用于治疗胆管缺乏相关病况的方法和组合物
JP7216381B2 (ja) Ｒｎａ作用抑制剤及びその利用
Guo et al. Efficacy of microRNA silencing by lipid-conjugated double-stranded antisense oligonucleotides
WO2023168202A2 (en) Certain dux4 inhibitors and methods of use thereof
Aigner et al. Therapeutic Modulation of MicroRNAs
Salva et al. 452. Co-Delivery of VEGF siRNA and IL-4 into Chitosan Nanoparticles in Breast Tumor Model of Rat
WO2018003988A1 (ja) 脳腫瘍を含む腫瘍の治療用核酸および組成物